Dan Roden

Peterson, Roden honored for translational medicine efforts

Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.

The study team included, from left, Douglas Johnson, MD, Dan Roden, MD, Javid Moslehi, MD, Joe-Elie Salem, MD, PhD, and Ali Manouchehri, MD.

Study identifies targeted therapy’s cardiac risks

After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Sara Van Driest, MD, PhD, with Dan Roden, MD, who nominated her for the award from the American Society of Clinical Pharmacology and Therapeutics.

Van Driest lands young investigator award from the American Society for Clinical Pharmacology and Therapeutics

Sara Van Driest, MD, PhD, assistant professor of Pediatrics and Medicine, recently received the 2019 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics.

Roden’s circulatory diseases research honored

Jun. 21, 2018—Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.

Roden’s circulatory diseases research honored

Vanderbilt University’s Dan Roden, MD, internationally known for his contributions to understanding how genetic variation affects drug response, has been named a recipient of the 2018 Louis and Artur Lucian Award for Research in Circulatory Diseases by McGill University in Montreal, Canada.

VUMC joins research network to fight atrial fibrillation

Vanderbilt University Medical Center (VUMC) has been selected by the American Heart Association (AHA) to participate in a six-member research network to advance treatment and prevention of atrial fibrillation (AFib), an irregular heart rate that increases the risk of stroke and other heart-related complications.

1 2 3 4 5